XLenti™ packaging and producer cell lines
XLenti™ stable clonal packaging and producer cell lines offer easy scale up, reduced cost of goods and reduced process complexity.
XLenti™ packaging and producer cell lines contain the same proven genetic system as the XLenti™ transient system, facilitating a smooth transition to this more scalable technology, and retaining all the optimisation benefits developed for the transient system.
Our up- and downstream process development experts improve titre through process optimisation, then support you to expedite on-boarding of technologies and facilitate technology transfer.
Evaluate and License
XLenti™ stable lentiviral packaging and producer cell lines provide scalable and efficient systems for high volume, high titre lentiviral production. XLenti™ packaging and producer cell lines are available for evaluation and license now.
XLenti™ packaging cell lines
OXGENE has successfully developed a suspension-mode, stable lentiviral packaging cell line platform using a proprietary Tet-inducible system. This demonstrates high titre lentiviral production with single plasmid transfection in both shake flask and bioreactor.
Our packaging cell lines are GMP-compliant and provide a simple, flexible platform from which to test multiple transgenes, or variants of a transgene, for further development.
We use a fully defined, serum/animal component free process to generate both our packaging and producer GMP-compliant HEK293 cell lines, which do not contain the SV40 Large-T antigen and remain stable in the absence of antibiotic selection, minimising the regulatory risks in transitioning to clinical use.
XLenti™ producer cell lines
Our packaging cell lines also form the basis of our GMP-compliant, animal component free producer cell lines, which permit transfection-free, large-scale production of lentiviral vectors for cell or gene therapies. This reduces the overall cost of goods and process complexity involved in clinical-scale viral vector production, while improving scalability and system reproducibility.
A further advantage of producer cell lines is the added potential for process development to improve viral titres once we've stably integrated your gene of interest , free from the process limitations imposed by transfection. Overall, lentiviral producer cell lines allow the consistent production of large quantities of lentiviral vector at lower cost.
OXGENE’s producer cell lines use our proprietary XLenti™ genetic system, which has codon optimised promoter and packaging sequences for increased translation efficiency, Tet inducible VSV-G and Gag-Pol expression, and low homology between expression cassettes for an improved safety profile.
We use a fully defined, serum/animal component free process to generate both our packaging and producer GMP-compliant HEK293 cell lines. Cell lines do not contain the SV40 Large-T antigen and remain stable in the absence of antibiotic selection, minimising the regulatory risks in transitioning to clinical use.
From our experts to yours: our scientists offer ongoing and detailed technical support so you can have complete confidence in the performance of our technologies once transferred to your own facilities.